Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab Switch Study in Plaque Psoriasis (aIMM)
NCT04102007Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2019
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 3 trial of risankizumab in plaque psoriasis, sponsored by AbbVie Inc.. Started Nov 2019; status: completed.
02
Drugs
risankizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04102007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04102007.